At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 389 enrolled
Drug / intervention
Japanese Encephalitis purified inactivated vaccinebiological
Likely dose
Japanese Encephalitis purified inactivated vaccine 6 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Controlled Phase 3 Study.
In Brief
A Phase 3 clinical trial evaluating Japanese Encephalitis purified inactivated vaccine for Japanese Encephalitis. Completed, enrolled 389 participants across 4 sites in 2 countries.
Detailed Summary
The objective is to demonstrate equivalence of three commercial IC51 batches in terms of geometric mean titers for anti-JEV neutralizing antibody
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJapanese Encephalitis
CountriesAustria, Germany
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedJan 2008
Primary CompletionFeb 2008
Study CompletionJun 2008
TodayJul 2026
First PostedJan 16, 2008
Enrollment StartDec 1, 2007
Primary CompletionFeb 1, 2008
Study CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 18.5 years ago
Interventions
Japanese Encephalitis purified inactivated vaccinebiological
IC51 6 mcg i.m. injection on Day 0 and Day 28